Early Phase 1 Chronic Fatigue Syndrome Trial, Recruiting NCT06472622 Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Condition: Chronic Fatigue Syndrome
Back to Chronic Fatigue Syndrome

Early Phase 1 Chronic Fatigue Syndrome Trial, Recruiting

NCT06472622
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For healthy volunteers:

  • People aged 18 to 50 who are in good general health, based on their medical history and/or a physical check-up
  • People who are willing and able to understand and sign a consent form, and are available to take part for the full duration of the study

For people with ME/CFS:

  • People aged 18 to 50 who have a formal diagnosis of ME/CFS that meets at least one of three recognised sets of diagnostic standards: the 1994 Fukuda Criteria, the 2003 Canadian Consensus Criteria, or the Institute of Medicine Diagnostic Criteria
  • People who are willing and able to understand and sign a consent form, and are available to take part for the full duration of the study

Who may not be able to join:

For healthy volunteers:

  • People who currently have a major neurological or psychiatric condition, such as stroke, Parkinson's disease, Alzheimer's disease, schizophrenia, or major depression
  • People who currently have another significant medical condition, such as kidney disease, liver disease, heart disease, or a chronic pain condition, that in the lead researcher's view could make participation unsafe or difficult
  • People who are currently taking medications that primarily affect the brain and nervous system, such as antidepressants or stimulants
  • People who have used opioid pain medications for more than two weeks at any point in the last two years, or at all in the last month
  • People with a current or past history of a substance use disorder, binge drinking, illegal drug use, or heavy tobacco use (more than 10 cigarettes per week)
  • People who use cannabis more than occasionally, defined as use on more than one or two days in the last two weeks (confirm with trial site)
  • People who use any other illicit drugs or misuse prescription medications (confirm with trial site)
  • People with a condition or injury that affects their grip
  • People with a condition or injury affecting their arms or legs that would change their skin's sensitivity to heat or cold pain testing, or make such testing unsafe
  • People for whom an MRI scan would be unsafe — for example, those with metal in the skull or eye, an implanted nerve stimulator, cochlear implant, cardiac pacemaker, defibrillator, or implanted pump; those with non-removable body piercings; those with claustrophobia; those unable to lie still for 90 minutes; or those who are pregnant or planning to become pregnant during the study
  • Staff members of the NINDS Brain Network Unit (BNU) and their immediate family members
  • People who do not speak English, as some of the study tools have not been validated in other languages

For people with ME/CFS:

  • People who have a major neurological or psychiatric condition in addition to their ME/CFS, such as stroke, Parkinson's disease, Alzheimer's disease, schizophrenia, or major depression
  • People who have another significant medical condition in addition to their ME/CFS, such as kidney disease, liver disease, heart disease, or a chronic pain condition, that in the lead researcher's view could make participation unsafe or difficult
  • People who are currently taking psychomotor stimulants, antipsychotics, or benzodiazepines
  • People who have used opioid pain medications for more than two weeks at any point in the last two years, or at all in the last month
  • People with a current or past history of a substance use disorder, binge drinking, illegal drug use, or heavy tobacco use (more than 10 cigarettes per week)
  • People who use cannabis more than occasionally, defined as use on more than one or two days in the last two weeks (confirm with trial site)
  • People who use any other illicit drugs or misuse prescription medications (confirm with trial site)
  • People with a condition or injury that affects their grip
  • People with a condition or injury affecting their arms or legs that would change their skin's sensitivity to heat or cold pain testing, or make such testing unsafe
  • People for whom an MRI scan would be unsafe — for example, those with metal in the skull or eye, an implanted nerve stimulator, cochlear implant, cardiac pacemaker, defibrillator, or implanted pump; those with non-removable body piercings; those with claustrophobia; those unable to lie still for 90 minutes; or those who are pregnant or planning to become pregnant during the study
  • Staff members of the NINDS Brain Network Unit (BNU) and their immediate family members
  • People who do not speak English, as some of the study tools have not been validated in other languages

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Eric M Wassermann, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Phone: (301) 480-9787

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
9 April 2025
Est. completion
30 June 2034

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Determine which regions of the SVN are specifically involved in the subjective experience of unpleasantness associated with sensations of pain.; Determine which regions of the SVN are specifically involved in the subjective experience of unpleasantness associated with sensations of physical effort.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov